Analyst Ranking
Bottom 19%
#4035 out of 4929 analysts
Average Return
-1.31%
Win Rate
38%6 out of 16
Risk vs Reward
Poor
Good

Carl Byrnes's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Brainsway LtdBWAY
+133.50%$2.00$4.67
2022-11-17 -
2023-11-16
Buy
Gw Pharmaceuticals PLCGWPH
+123.25%$97.65$218.00
2020-04-08 -
2021-04-08
Buy
Brainsway LtdBWAY
+94.13%$6.82$13.24
2024-08-07 -
2025-07-03
Buy
Spectral Ai IncMDAI
+61.45%$1.66$2.68
2024-08-12 -
2025-07-03
Buy
Brainsway LtdBWAY
+37.92%$9.60$13.24
2024-10-03 -
2025-07-03
Buy

Carl Byrnes Analyst Color

Get additional color on Carl Byrnes's coverage of popular stocks

Carl Byrnes's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Biolife Solutions IncBLFS
2Buy$31.00+35.73%Maintains
6 months ago
Trisalus Life Sciences IncTLSI
1Buy$12.50+146.55%Initiates Coverage On
8 months ago
Brainsway LtdBWAY
3Buy$12.50-5.59%Maintains
9 months ago
Oncternal Therapeutics IncONCT
1Hold$2.00+279.51%Downgrades
10 months ago
Spectral Ai IncMDAI
1Buy$6.00+123.88%Initiates Coverage On
a year ago
Amarin Corp PLCAMRN
1Hold$25.00N/AMaintains
2 years ago
Cardio Diagnostics Holdings IncCDIO
1Buy$240.00N/AInitiates Coverage On
2 years ago
Polarityte IncPTEIQ
1Buy$1.00N/AMaintains
3 years ago
Vtv Therapeutics IncVTVT
2Buy$80.00N/AMaintains
3 years ago
Nabriva Therapeutics PLCNBRVF
1Buy$50.00N/AMaintains
3 years ago
Flexion Therapeutics IncFLXN
1HoldN/AN/ADowngrades
4 years ago
Adamas Pharmaceuticals IncADMS
1Hold$8.50N/ADowngrades
4 years ago
Skylight Health Group IncSLHGF
1Buy$9.00N/AInitiates Coverage On
4 years ago
Mimedx Group IncMDXG
1Buy$23.00N/AInitiates Coverage On
4 years ago
Esperion Therapeutics IncESPR
4Hold$24.00N/AMaintains
4 years ago
Gw Pharmaceuticals PLCGWPH
1Buy$128.00N/AInitiates Coverage On
5 years ago
Aytu Biopharma IncAYTU
1Buy$2,000.00N/AInitiates Coverage On
7 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.